HC Wainwright Brokers Lower Earnings Estimates for ALGS

Aligos Therapeutics, Inc. (NASDAQ:ALGS) – HC Wainwright dropped their Q1 2025 EPS estimates for Aligos Therapeutics in a report released on Tuesday, March 11th. HC Wainwright analyst E. Arce now anticipates that the company will post earnings per share of ($2.37) for the quarter, down from their prior forecast of ($1.85). HC Wainwright currently has a “Buy” rating and a $70.00 price target on the stock. The consensus estimate for Aligos Therapeutics’ current full-year earnings is ($10.36) per share. HC Wainwright also issued estimates for Aligos Therapeutics’ Q2 2025 earnings at ($2.35) EPS, Q3 2025 earnings at ($2.62) EPS, Q4 2025 earnings at $5.91 EPS, FY2025 earnings at ($1.31) EPS, FY2026 earnings at ($8.97) EPS, FY2027 earnings at ($9.99) EPS, FY2028 earnings at ($9.24) EPS and FY2029 earnings at ($9.12) EPS.

Aligos Therapeutics Stock Performance

Shares of ALGS stock opened at $10.81 on Thursday. Aligos Therapeutics has a 52-week low of $6.76 and a 52-week high of $46.80. The stock has a market cap of $38.79 million, a PE ratio of -0.81 and a beta of 2.52. The firm’s 50 day moving average price is $25.48 and its two-hundred day moving average price is $20.46.

Aligos Therapeutics (NASDAQ:ALGS) last announced its quarterly earnings data on Monday, March 10th. The company reported ($13.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.63) by ($10.45). Aligos Therapeutics had a negative net margin of 1,283.19% and a negative return on equity of 114.34%. The business had revenue of $0.63 million during the quarter, compared to the consensus estimate of $0.43 million. During the same period in the previous year, the business posted ($5.50) earnings per share.

Hedge Funds Weigh In On Aligos Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Drive Wealth Management LLC bought a new position in shares of Aligos Therapeutics during the fourth quarter worth $916,000. Golden State Wealth Management LLC bought a new stake in Aligos Therapeutics in the 4th quarter valued at $107,000. AlphaMark Advisors LLC lifted its position in Aligos Therapeutics by 1,000.0% in the 4th quarter. AlphaMark Advisors LLC now owns 1,100 shares of the company’s stock valued at $44,000 after acquiring an additional 1,000 shares in the last quarter. Northern Trust Corp bought a new stake in Aligos Therapeutics in the 4th quarter valued at $205,000. Finally, Tower Research Capital LLC TRC lifted its position in Aligos Therapeutics by 2,073.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 652 shares of the company’s stock valued at $26,000 after acquiring an additional 622 shares in the last quarter. 60.43% of the stock is owned by institutional investors.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).